FIELD: chemistry.
SUBSTANCE: present invention relates to a compound of chemical formula 1, having inhibitory activity on janus-kinase (JAK3) and Bruton tyrosine kinase (BTK), or a pharmaceutically acceptable salt thereof. In one embodiment, in chemical formula 1, X is O; A is a ring selected from a group consisting of benzothiazole, isothiazole, isoxazole, pyrazole, pyrrole, thiazole, thiophene and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine; R1 denotes hydrogen; C1-4 alkyl, unsubstituted or substituted with one substitute selected from a group consisting of C1-4 alkoxy and N(C1-4 alkyl)2; C1-4 alkoxy; C1-4 haloalkyl; C3-6 cycloalkyl; N(C1-4 alkyl)2; pyrazolyl unsubstituted or substituted with one or two C1-4 alkyl groups; or 
, where Y1 is NH, N(C1-4 alkyl) or O; Y2 is CH or N; L is a bond, C1-4 alkylene or CO; R2 denotes hydrogen, C1-4 alkyl or halogen, and R3 is C1-4 alkyl substituted with halogen; C2-4 alkenyl unsubstituted or substituted with halogen; or C2-4 alkynyl. In another embodiment in chemical formula 1 X is O; A is a ring selected from the group consisting of benzene and pyridine; R1 denotes hydrogen; C1-4 alkyl, unsubstituted or substituted with one substitute selected from a group consisting of C1-4 alkoxy and N (C1-4 alkyl)2 ; C1-4 alkoxy; C1-4 haloalkyl; C3-6 cycloalkyl; N(C1-4 alkyl)2; pyrazolyl unsubstituted or substituted with one or two C1-4 alkyl groups; or , where Y1 is NH, N (C1-4 alkyl) or O; Y2 is CH or N; L is a bond, C1-4 alkylene or CO; R2 is halogen, and R3 is C1-4 alkyl substituted with halogen; C2-4 alkenyl unsubstituted or substituted with halogen; or C2-4 alkynyl. Present invention also refers to a pharmaceutical composition containing said compounds or their pharmaceutically acceptable salts.
[chemical formula 1].
EFFECT: pharmaceutical composition can be used for preventing or treating an inflammatory disease, an autoimmune disease, a proliferative disease, a hyperproliferative disease, an immuno-mediated disease, cancer or tumour.
9 cl, 1 tbl, 50 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF OXIFLUOROPIPERIDINE AS A KINASE INHIBITOR | 2018 |
|
RU2758370C1 |
| PYRAZOLOPYRIMIDINE DERIVATIVES AS A KINASE INHIBITOR | 2017 |
|
RU2714206C1 |
| DERIVATIVES OF AMINOFLUORPIPERIDINE AS A KINASE INHIBITOR | 2018 |
|
RU2762637C1 |
| HETEROARYL DERIVATIVE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, A METHOD FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAID ACTIVE SUBSTANCE | 2016 |
|
RU2719367C2 |
| AMINOMETHYLPIPERIDINE DERIVATIVES AS KINASE INHIBITOR | 2018 |
|
RU2756505C1 |
| 1,2,3,4-TETRAHYDROPYRAZOLO-[5,1-C]-(1,2,4)-TRIAZINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION INHIBITING PRODUCING AN INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR, METHOD OF PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PATIENTS WITH DISEASES MEDIATED BY INTERLEUKIN AND TUMOR NECROSIS FACTOR | 1994 |
|
RU2124517C1 |
| BICYCLIC KETONES AND METHODS OF THEIR USE | 2018 |
|
RU2797922C2 |
| PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | 2008 |
|
RU2464262C2 |
| COMPOSITIONS SUITABLE FOR TREATING DISORDERS ASSOCIATED WITH KIT | 2014 |
|
RU2706235C2 |
| HETEROARYL COMPOUNDS AS TKB INHIBITORS AND USE THEREOF | 2015 |
|
RU2742122C2 |
